Pharmaceuticals and well-complemented by Diagnostics. Interestingly, although Roche’s management claims minimal COVID-related Q1 disruption, there were delayed appointments for some chronic diseases and a drug shortage. While it is difficult to believe that the performance in the coming quarters will continue unscathed, Roche – by virtue of its competitive offerings and balance sheet strength – should be able to sail through with minimal damage.
23 Apr 2020
Strong Q1 growth (for now) dodges COVID-19
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Q1 growth (for now) dodges COVID-19
Roche Holding Ltd Dividend Right Cert. (RHO5:ETR) | 0 0 1.1% | Mkt Cap: 194,207m
- Published:
23 Apr 2020 -
Author:
Surbhit Gupta -
Pages:
5
Pharmaceuticals and well-complemented by Diagnostics. Interestingly, although Roche’s management claims minimal COVID-related Q1 disruption, there were delayed appointments for some chronic diseases and a drug shortage. While it is difficult to believe that the performance in the coming quarters will continue unscathed, Roche – by virtue of its competitive offerings and balance sheet strength – should be able to sail through with minimal damage.